BioSpace News Archive

With Crew’s appointment, the total number of directors is seven.

Bluegrass Vascular Technologies today announced the enrollment of its first patients in the SAVE-US pivotal trial.

The data, presented at the Keystone Symposia Conference, A3: T Cell Dysfunction, Cancer and Infection, being held January 16-20, 2018, at the Beaver Run Resort, Breckenridge, CO, provide indication for a dominant role of the PVRIG/TIGIT axis in cancer evasion of immune response in multiple cancers.

The successful live case was performed by Dr. Spyrantis and Professor Banai in the Sana-Klinikum Lichtenberg.

AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc., today announced that AgeX will present in a Plenary session, “Stem Cell Innovations That Will Change the World – Part 2,” at the World Stem Cell Summit (WSCS) on Thursday, January 25, 2018 at the Hyatt Regency Miami.

Enertec will develop and produce fully automated testing systems for medical calibration devices treating heart rhythm disorders.

Amneal Pharmaceuticals has launched budesonide capsules, 3 mg, an AB-rated equivalent to Entocort EC.

Protalex today announced that following a planned interim analysis of data from the fourth dose cohort of its European Phase 1b study of PRTX-100 (PRTX-100-203 Study) in adults with persistent/chronic Immune Thrombocytopenia (ITP), the Company has initiated enrollment in the fifth and highest dose cohort of this dose-escalating study.

The results show a near 75% decrease in readmission rates for joint arthroplasties conducted under its Episode of Care Assurance Program.